Abstract:Rejection of solid organ transplant and graft versus host disease (GvHD) continue to be challenging in post transplantation management. The introduction of calcineurin inhibitors dramatically improved recipients' short-term prognosis. However, long-term clinical outlook remains poor, moreover, the lifelong dependency on these toxic drugs leads to chronic deterioration of graft function, in particular the renal function, infections and de-novo malignancies. These observations led investigators to identify alternative therapeutic options to promote long-term graft survival, which could be used concomitantly, but preferably, replace pharmacologic immunosuppression as standard of care. Adoptive T cell (ATC) therapy has evolved as one of the most promising approaches in regenerative medicine in the recent years. A range of cell types with disparate immunoregulatory and regenerative properties are actively being investigated as potential therapeutic agents for specific transplant rejection, autoimmunity or injury-related indications. A significant body of data from preclinical models pointed to efficacy of cellular therapies. Significantly, early clinical trial observations have confirmed safety and tolerability, and yielded promising data in support of efficacy of the cellular therapeutics. The first class of these therapeutic agents commonly referred to as advanced therapy medicinal products have been approved and are now available for clinical use. Specifically, clinical trials have supported the utility of CD4 + CD25+FOXP3+ regulatory T cells (Tregs) to minimize unwanted or overshooting immune responses and reduce the level of pharmacological immunosuppression in transplant recipients. Tregs are recognized as the principal orchestrators of maintaining peripheral tolerance, thereby blocking excessive immune responses and prevent autoimmunity. Here, we summarize rationale for the adoptive Treg therapy, challenges in manufacturing and clinical experiences with this novel living drug and outline future perspectives of its use in transplantation.

Mini-Review: Tregs as a Tool for Therapy—Obvious and Non-Obvious Challenges and Solutions

The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology

Regulatory CAR-T cells in autoimmune diseases: Progress and current challenges

Regulatory T cells (Tregs) and their therapeutic potential against autoimmune disorders – Advances and challenges

Current status and perspectives of regulatory T cell-based therapy

Therapy with regulatory T-cell infusion in autoimmune diseases and organ transplantation: A review of the strengths and limitations

Induced Regulatory T Cells as Immunotherapy in Allotransplantation and Autoimmunity: Challenges and Opportunities

T regulatory cells as an immunotherapy for transplantation.

T Regulatory Cells As an Immunotherapy for Transplantation

TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges

Tregs in transplantation tolerance: role and therapeutic potential

Treg Enhancing Therapies to Treat Autoimmune Diseases

Clinical adoptive regulatory T Cell therapy: State of the art, challenges, and prospective

Chimeric antigen receptor Treg therapy in transplantation

Treg cell therapy: How cell heterogeneity can make the difference

Treg cell-based therapies: challenges and perspectives

Regulatory T lymphocytes as a treatment method for rheumatoid arthritis - Superiority of allogeneic to autologous cells

Genetic engineering of regulatory T cells for treatment of autoimmune disorders including type 1 diabetes

TREG-cell therapies for autoimmune rheumatic diseases

Human OX40L-CAR-Tregs target activated antigen-presenting cells and control T cell alloreactivity

From promise to practice: CAR T and Treg cell therapies in autoimmunity and other immune-mediated diseases